Abstract Details
|
Amie L. Hiller, MD
PRESENTER |
The institution of Dr. Hiller has received research support from Admas Pharmaceuticals. |
| No disclosure on file | |
| No disclosure on file | |
| Shu-Ching Hu, MD (University of Washington) | No disclosure on file |
| Cyrus P. Zabetian, MD (VA Puget Sound Health Care System) | The institution of Dr. Zabetian has received research support from American Parkinson Disease Association. The institution of Dr. Zabetian has received research support from Department of Veterans Affairs. The institution of Dr. Zabetian has received research support from NIH. Dr. Zabetian has a non-compensated relationship as a Member, Scientific Advisory Council with Lewy Body Dementia Association that is relevant to AAN interests or activities. |
| James B. Leverenz, MD, FAAN (Cleveland Clinic) | Dr. Leverenz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia. Dr. Leverenz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Leverenz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. |
| Kathryn A. Chung, MD (Oregon Health Sciences Univ) | The institution of Dr. Chung has received research support from Department of Veteran's Affairs. |
| Thomas J. Montine, MD, PhD | Dr. Montine has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Enable Medicine. Dr. Montine has stock in Enable Medicine. The institution of Dr. Montine has received research support from NIH. The institution of Dr. Montine has received research support from MJFF. Dr. Montine has received intellectual property interests from a discovery or technology relating to health care. Dr. Montine has received publishing royalties from a publication relating to health care. |
| No disclosure on file | |
| Joseph F. Quinn, MD, FAAN (OHSU Neurology) | Dr. Quinn has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Retrophin. Dr. Quinn has received personal compensation in the range of $500-$4,999 for serving as a DSMB with Alzheimer's Disease Cooperative Study. Dr. Quinn has received personal compensation in the range of $500-$4,999 for serving as a DSMB with Alzheimer's Therapeutic Research Institute. Dr. Quinn has a non-compensated relationship as a consultant with Cognition Therapeutics that is relevant to AAN interests or activities. |